Segall Bryant Hamill LLC Sells 44,983 Shares of Regal Rexnord Co.
RGC Stock | USD 5.52 0.34 5.80% |
About 62% of Regencell Bioscience's investor base is looking to short. The analysis of the overall investor sentiment regarding Regencell Bioscience Holdings suggests that many traders are alarmed. The current market sentiment, together with Regencell Bioscience's historical and current headlines, can help investors time the market. In addition, many technical investors use Regencell Bioscience stock news signals to limit their universe of possible portfolio assets.
Regencell |
Segall Bryant Hamill LLC trimmed its position in shares of Regal Rexnord Co. by 13.6 percent in the third quarter, Holdings Channel reports. The fund owned 284,850 shares of the companys stock after selling 44,983 shares during the quarter. Regal Rexnord comprises approximately 0.6 percent of Segall Bryant Hamill LLCs investment
Read at thelincolnianonline.com
Regencell Bioscience Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Regencell Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Regencell Bioscience Fundamental Analysis
We analyze Regencell Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Regencell Bioscience is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Regencell Bioscience Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regencell Bioscience stock to make a market-neutral strategy. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics with similar companies.
Peers
Regencell Bioscience Related Equities
PROC | Procaps Group | 7.56 | ||||
ANIP | ANI Pharmaceuticals | 1.95 | ||||
PBH | Prestige Brand | 1.14 | ||||
COSM | Cosmos Health | 0.63 | ||||
SBFMW | Sunshine Biopharma | 0.87 | ||||
PAHC | Phibro Animal | 0.90 | ||||
COLL | Collegium Pharmaceutical | 1.50 |
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |